Events
Top 10 Glance stories of 2025
Find out which news was most trending this year.
Products
Your rundown: 2025 approvals and launches
Take a trip down memory lane for a look at this year’s latest additions to the ophthalmic space.
Research
Migraines could indicate higher likelihood for CSCR development
Study identifies almost 3-fold increased risk of CSCR in patients with migraines.
Products
Rinsada expands irrigating eyelid retractor distribution to Canada
Already FDA-cleared in the U.S., the medical device is now registered by Health Canada and only available through online retailer Eye Drop Shop.
Pipeline
FDA extends reproxalap's PDUFA to March 2026
Updated target action date applies to Aldeyra’s third NDA submission of the investigational DED eye drop.
Pipeline
OKYO Pharma reports favorable phase 2 data for NCP asset
Formerly OK-101, urcosimod is formulated for topical application, with latest results demonstrating a favorable impact on corneal nerve health.
Research
Could DR screenings benefit CVD detection?
Study explores potential of unexpected early advantages for patients with type 2 diabetes mellitus during routine eye exams.
Pipeline
Cloudbreak advances vascularized pinguecula eye drop to phase 3 trials
Company’s investigational multi-kinase inhibitor targeting VEGFs and PD-GFRs met phase 2 primary endpoint of conjunctival hyperemia earlier this year
Research
Real-world study supports AmblyoPlay as vision training tool for pediatric anisometropic amblyopia
Exploratory pilot study evaluates the impact of short, daily sessions of interactive gaming to improve visual skills over a 6-month period.
Research
Clinicians are under-utilizing this AI-based DR screening system
EyeArt system demonstrates high diagnostic accuracy in detecting DR, though obstacles remain for real-world implementation.
Products
FDA approves Alembic Pharma's loteprednol etabonate and tobramycin ophthalmic suspension
Generic of Bausch + Lomb’s ZYLET for steroid-responsive inflammatory ocular conditions qualifies for 6 months of market exclusivity once commercially launched.
Research
Study: enVista Aspire IOL delivers expanded intermediate vision without sacrificing distance
Prospective study evaluates the enhanced monofocal IOL among patients undergoing standard phaco.
Products
Scope's OPTASE HYLO Forte Dry Eye Drops offer long-lasting symptom relief
Clinical experts share OD-MD insights into the advanced artificial tears’ hydrating PF formulation with active glycerin and hyaluronic acid.
Business
Alcon proposes higher bid for STAAR Surgical acquisition
Amended merger agreement increases total equity value of deal by $150 million; meanwhile, a major shareholder is urging against the sale.
Pipeline
Azura gets positive FDA feedback on NDA submission for MGD ointment
Positive pre-NDA meeting for selenium sulfide ointment precedes planned phase 3 data release in Q1 2026 and regulatory submission in H2 2026.
Research
Study links DME to systemic microvascular complications in diabetes
Analysis highlights the interconnected relationship between DR, neuropathy, and nephropathy in T2DM.
Pipeline
SeaBeLife and Unither to formulate and develop retinal degenerative disorder formulation
Collaboration focuses on accelerating development of SBL03, formulated for topical delivery to target retinal cell necrosis in GA and dry AMD
Pipeline
Ocular Therapeutix plans for NDA submission of AXPAXLI for wet AMD
Company expects to submit package in Q1 2026, following the anticipated release of positive 1-year data from the phase 3 SOL-1 trial.
Pipeline
EyeYon Medical secures IDE approval for study on first artificial endothelial layer
IDE approval allows for clinical study initiation to evaluate EndoArt, the first-ever synthetic implant for treating corneal edema and improving vision.
Business